SCHEMBL17446951

SCHEMBL17446951

C=C1C[C@@H](C)C(c2ccc(N3CCN(C)CC3)cc2)=NN1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE3B Q13370 9/20 0.73
▸ PDE3A Q14432 9/20 0.73
▸ KDM4E B2RXH2 3/20 0.44
▸ MAPT P10636 3/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ GFER P55789 2/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ PDE4A P27815 1/20 0.42
▸ PDE4B Q07343 1/20 0.42
▸ PDE4C Q08493 1/20 0.42
▸ PDE4D Q08499 1/20 0.42
▸ GAA P10253 1/20 0.40
▸ ADRA2C P18825 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ PTK2B Q14289 1/20 0.40
▸ ESR2 Q92731 1/20 0.40
▸ MELK Q14680 1/20 0.39
▸ JAK2 O60674 1/20 0.39
▸ NPC1 O15118 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17446950 0.88 PDE3B (0.56) PDE3BPDE3AKDM4EMAPTALDH1A1
SCHEMBL17446940 0.87 PDE3B (0.73) PDE3BPDE3AKDM4EMAPTALDH1A1
SCHEMBL17446952 0.87 PDE3B (0.73) PDE3BPDE3AKDM4EMAPTALDH1A1
SCHEMBL21970679 0.84 PDE3B (1.00) PDE3BPDE3AKDM4EMAPTALDH1A1
SCHEMBL16157015 0.84 PDE3B (1.00) PDE3BPDE3AKDM4EMAPTALDH1A1
SCHEMBL17446973 0.78 PDE3B (0.52) PDE3BPDE3AKDM4EMAPTALDH1A1
SCHEMBL17446955 0.77 PDE3B (0.43) PDE3BPDE3AMAPTPDE4APDE4B
SCHEMBL17446919 0.76 PDE3B (0.46) PDE3BPDE3APDE4APDE4BPDE4C
SCHEMBL17446918 0.76 PDE3B (0.42) PDE3BPDE3AMAPTPDE4APDE4B
SCHEMBL17446937 0.76 PDE3B (0.42) PDE3BPDE3AKDM4EMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9890127-B2 Compounds and compositions for the treatment of cancer THE BROAD INSTITUTE, INC. (US) 2018-02-13 — — US disclosed
US-20160016913-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER THE BROAD INSTITUTE, INC. (US) 2016-01-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160016913-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER TP53, RB1, CDK4 PDE3B 2667/4885PDE3A 2661/4885KDM4E 1947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback